Background:The exact aetiology and pathogenesis of pterygium remains unclear but it is more common in people with excessive outdoor exposure to sunlight and wind, such as those who work outdoors. Pterygium is of great concerns to both surgeons and patients, as it has been shown to recur in up to 97% of patients within one year after surgical removal. Different adjuvant procedures like lamellar corneal graft, irradiation etc. to prevent recurrence is not encouraging. Of late a new anticancer drug named Daunorubicine (0.02%) has been used intraoperatively in pterygium surgery by one of the study with promising results. Pterygium excision with Conjunctival Autografting is very popular technique to prevent recurrence with very few side effects. This is being tried out with success in different country.